Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Technologies, Phenomenex

Agilent Technologies this week launched the High Sensitivity Protein 250 Kit for the company’s 2100 bioanalyzer. The kit is designed for pharmaceutical QA/QC and life science research applications and detects proteins down to as little as 1 picogram per microliter, which Agilent said is comparable to or better than silver-staining slab gels.
The kit features a dynamic range of four orders of magnitude for quantification and covers a sizing range of 10 to 250 kiloDaltons. Separation, quantitation, and purity measurements can be done in a single step, and typical throughput for QA/QC is 10 samples per hour, Agilent said in a statement. Each kit analyzes up to 100 samples.

Phenomenex introduced the 3 micrometer C18 300 Å HPLC column this week. The C18 reverse phase column is the most efficient of the company’s Jupiter line of products of protein characterization and purification, Phenomenex said in a statement, and provides better resolution and sharper peaks than other phases “enabling the separation of closely eluting proteins.”

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.